All episodes
Episode 343: ESMO 2024 - TiNivo-2 Trial
Episode 342: ESMO 2024 Preview with Silke Gillessen
Episode 341: Hormone Resistance in Prostate Cancer
Episode 340: Cancer Immunity Cycle Update
Episode 339: Tres Uramigas analizan lineamientos de ESMO para GU
Episode 338: RCC: Debulking Nephrectomy, Adjuvant Therapy Future and More
Episode 337: Updated NCCN Guidelines in RCC
Episode 336: Which patients are not suitable for 1st line EVP in bladder cancer
Episode 335: Novel immune therapies for renal cancer
Episodio 334 en español: Tres Uramigas ASCO 2024
Episode 333: The Uromigos Cup - The Netherlands
Episode 332: The Uromigos Cup - Germany's Entry
Episode 331: AUA 2024 NMIBC Highlights
Episode 330: ASCO 2024 Highlights
Episode 329: Japan in the Uromigos Cup qualifying round
Episode 328 ASCO24: Emergency podcast - what the NADINA trial means for preoperative GU cancer studies
Episode 327 ASCO24: CM901 and EV302 Efficacy and QOL Updates
Episode 326 ASCO24: KIM-1 in Renal Cancer
Episode 325 ASCO24: KN426 and the CLEAR trial - tissue based biomarkers for kidney cancer
Episode 324 ASCO24: SURE1 neoadjuvant sacituzumab govitecan in UC
Episode 323 ASCO24: TDXD in Bladder Cancer
Episode 322 ASCO24: The role of ctDNA in the TheraP trial (LuPSMA vs cabazitaxel in CRPC)
Episode 321 ASCO24: CHAARTED-2 in prostate cancer - is the sequel as good as the original?
Episode 320: Team Canada's entry for the Uromigos Cup
Episode 319: ASCO 2024: A Preview of GU Data
Episode 318: The Lancet Commission on prostate cancer: planning for a surge in cases
Episode 317: AUA 2024 Preview with the AUA Secretary
Episode 316: APCCC 2024 Summary with Silke Gillessen
Episode 315: APCCC 2024 Quickfire - Bone health, hot flashes and gynecomastia in prostate cancer
Episode 314: APCCC 2024 Cardiovascular risks with hormone therapy in prostate cancer
Episode 313: APCCC 2024 Debate - Radiation therapy in advanced disease
Episode 312: APCCC 2024 Radiation therapy after surgery for prostate cancer
Episode 311: The Uromigos Paper of the Month - The POUT Trial
Episode 310: Dosing and duration of drugs from a cost perspective
Episode 309: EAU24 Checkmate 274 - OS for adjuvant nivolumab in bladder cancer
Episode 308: EAU24 IMVIGOR 011 - Outcome of ctDNA negative patients post-cystectomy
Episode 307: Bladder-Sparing Approaches Part 2
Episode 306: The Uromigos Paper of the Month - Chemo/Nivo as a bladder sparing approach in UC
Episode 305: FDA and Oncology Clinical Trials
Episode 304: A PSMA CD3 Bispecific T-cell Engager in CRPC
Episode 303: Community GU Oncology
Episode 302: Part 2- Adjuvant Therapy in solid tumors
Episode 301: Cancer research from a global perspective.
Episode 300: Adjuvant PD1 Therapy in Solid Tumours
Episode 299: Androgen receptor ligand-directed degrader BMS-986365
Episode 298: ASCO GU 2024 Highlights
Episode 297: ASCO GU 2024: CONTACT2 Part 2 - The Aftermath
Episode 296: ASCO GU 2024: Novel approaches to QOL and belzutifan
Episode 295: ASCO GU 2024: Adjuvant Therapy in Renal Cancer
Episode 294: ASCO GU 2024: Adjuvant Pembrolizumab in Bladder Cancer
Episode 293: ASCO GU 2024: BRCAaway and CONTACT2
Episode 292: ASCO GU 2024: HPN328 - A Tri-Specific T Cell Engager in Prostate Cancer
EEpisode 291: ASCO GU 2024: CONTACT2 - Cabozantinib and Atezolizumab in Prostate Cancer
Episode 290: ASCO GU 2024 Preview
Episode 289: The Uromigos Paper of the Month - TALAPRO2 in Nature Medicine
Episode 288: APCCC #3: Controversies around Radiotherapy
Episode 287 APCCC: Early Discontinuation of Therapy in HSPC
Episode 286: APCCC Prostate Cancer Meeting Overview
Episode 285: Holiday Special: Renal Cancer in 2023
Episode 284: Tres amigas: Lo más destacado del cáncer en urología en 2023
Episode 283: Holiday Special: Prostate Cancer in 2023
Episode 282: Holiday Special: Bladder Cancer in 2023
Episode 281: The Uromigos Paper of the Month - Lu-177 with Pembrolizumab in Prostate Cancer
Episode 280: IKCS 2023 Overview
An apology
Episode 279: Management of IO-resistant RCC at #UromigosLive 2023
Episode 278: Current and Future Status of Radioligand Therapy at #UromigosLive 2023
Episode 277: NMIBC Discussion at #UromigosLive 2023
Episode 276: ESMO 2023 Highlights
Episode 275: Live meeting preview for #UromigosLive 2023 in Nashville
Episode 274: ESMO 2023 STEAP1/BiTE in CRPC shows promise
Episode 273: ESMO 2023 - Toripalimab and axitinib in clear cell RCC
Episode 272: ESMO 2023 - EV302 and CM901 in 1st line bladder cancer
Episode 271: ESMO 2023 - THOR: Erdafitinib in bladder cancer
Episode 270: ESMO 2023 - Belzutifan in renal cancer
Episode 269: ESMO 2023 - antibody drug conjugate doublets in UC
Episode 268: ESMO 2023 - Enzalutamide and 177Lu-PSMA-617 in CRPC with Louise Emmett
Episode 267: ESMO preview - things to look out for at the meeting
Episode 266: Radiotherapy for prostate cancer
Episode 265: Brachytherapy with Jeff Michalski
Episode 264: Prostatectomy vs RT vs surveillance- the PROTECT trial
Episode 263: Toni Choueiri and papillary renal cancer
Episode 262: Paper of the month abiraterone +/- cabazitaxel in CRPC.
Episode 261: part 2 ctDNA in bladder cancer
Episode 260: Celeste Simon: how to make a career in translation science work.
Episode 259: Cystectomy for bladder cancer
Episode 258: Curative radiotherapy for bladder cancer: Golden Ticket Winner #1
Episode 257: Chana Weinstock from the FDA
Episode 256: ctDNA in urothelial studies.
Episode 255: How to get an academic paper accepted
Episode 254: New RCC studies at KCRS 2023 with Laurence Albiges
Episode 253: Patients' perspectives on adjuvant and 1st line RCC
Episode 252: Talazoparib and its FDA approval in CRPC
Episode 251: Final part of VEGF/TKI vs IPI/NIVO discussion
Episode 250: Bob Motzer discusses IPI/Nivo vs VEGF/PD1
Episode 249: ASCO 2023 emergency podcast IPI/NIVO vs VEGF/PD1 in kidney cancer
Episode 248: ASCO23 GU highlights
Episode 246: ASCO 2023: EV pembro and erdafitinib +/- cetrelimab in 1st line UC
Episode 245: ASCO 2023 - CONTACT-03 cabozantinib +/- atezolizumab in renal cancer
Episode 244: ASCO 2023 PEACE-1 in CRPC